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Background: Although CB1, the most abundant neuronal receptors, and CB2 receptors are co-expressed in neurons, the
CB1-CB2 relationship is unknown.
Results: CB1 and CB2 receptors form heteromers in neuronal cells and in the brain.
Conclusion: Activation of either receptor leads to negative modulation of the partner receptor via heteromers.
Significance: These heteromers may explain previous conflicting results and serve as therapeutic targets.
Exploring the role of cannabinoid CB2 receptors in the brain,
we present evidence of CB2 receptor molecular and functional
interaction with cannabinoid CB1 receptors. Using biophysical
and biochemical approaches, we discovered that CB2 receptors
can form heteromers with CB1 receptors in transfected neuro-
nal cells and in rat brain pineal gland, nucleus accumbens,
and globus pallidus. Within CB1-CB2 receptor heteromers
expressed in a neuronal cell model, agonist co-activation of CB1
and CB2 receptors resulted in a negative cross-talk in Akt phos-
phorylation and neurite outgrowth. Moreover, one specific
characteristic of CB1-CB2 receptor heteromers consists of both
the ability of CB1 receptor antagonists to block the effect of CB2
receptor agonists and, conversely, the ability of CB2 receptor
antagonists to block the effect of CB1 receptor agonists, showing
a bidirectional cross-antagonismphenomenon. Taken together,
these data illuminate the mechanism by which CB2 receptors
can negatively modulate CB1 receptor function.
The endocannabinoid system is known to have a broad
impact on a variety of tissues. It has been shown to heavily
influence cardiovascular and immune systems as well as to con-
trol progenitor cell proliferation (1–3). More recently, the
endocannabinoid system has emerged as a major player in the
complex web of neuromodulators, constituting a new intercel-
lular communication networkmainly involved in the control of
neurotransmitter release (4–7). By acting as retrograde mes-
sengers at various synapses, these endogenous arachidonic acid
derivatives participate in controlling processes, such as motor
activity, memory and learning, appetite, emesis, nociception,
and somemotivational responses (8–14). There are two known
cannabinoid receptors, CB1 and CB2, with strong evidence of a
third in the form of GPR55, and all have been considered as
therapeutic targets for basal ganglia disorders (15, 16). CB1
receptors mediate psychoactivity, whereas CB2 receptor-selec-
tive agonists lack psychoactivity but are implicated in the con-
trol of fundamental neural cell processes, such as proliferation
and survival, and their pharmacological manipulationmight be
useful for both delaying the progression of neurodegenerative
disorders and inhibiting the growth of glial tumors (17, 18). CB1
is the most abundant receptor in the central nervous system,
and, besides its classical influence on mood and emotion, it has
been demonstrated to play a role in the modulation of memory
processing and in metabolism (19). The ubiquitous expression
pattern of CB1 receptors reflects the complexity and the variety
of functions the endocannabinoid system impacts in neuronal
activity. CB1 receptors are often localized presynaptically,
where their stimulation usually inhibits neurotransmitter
release (4, 20, 21). In the striatal spine module, CB1 receptors
are localized both pre- and postsynaptically (22). Presynapti-
cally, CB1 receptors are localized in GABAergic terminals of
interneurons or collaterals from medium spiny neurons and
also in glutamatergic but not in dopaminergic terminals (23–
27). Postsynaptically, CB1 receptors are localized in the soma-
todendritic area of medium spiny neurons (23–25), and both
enkephalinergic and dynorphinergic medium spiny neurons
express CB1 receptors (28). The related receptor, CB2, tradi-
tionally was thought to be expressed in peripheral tissue, where
it can help control inflammation and various immunological
responses (1), but recent reports have suggested that it too can
be found in the brain (albeit at a lower expression level thanCB1
receptors) (29) and can impact a variety of neuronal processes.
Multiple studies have demonstrated the expression of CB2
receptors in different non-neuronal (30–33) and neuronal pop-
ulations (31, 34–38) where CB2 receptors show a preferred
postsynaptic localization (31, 35–37).
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BothCB1 andCB2 receptors aremembers of theGPCR4 fam-
ily and are Gi/Go-protein-coupled receptors (39). Agonist acti-
vation triggers inhibition of adenylyl cyclase and voltage-gated
calcium channels, activation of potassium channels, mitogen-
activated protein kinase (MAPK), and phosphoinositide-3
kinase (PI3K)/Akt signaling pathways (40, 41). Initially, CB1
and CB2 receptors, like other GPCRs, were thought to have
acted as single signaling receptors, but studies in the last decade
have convincingly shown that certain GPCRs in a variety of
different tissues can also form homodimers and even hetero-
mers (42). For the cannabinoid receptors, heteromers have
been shown to exist between CB1 and the dopamine and aden-
osine receptors (43–47) as well as with angiotensin (AT1) (48),
opioid 1 (49), and orexin OX1 receptors (50). However, to
date, no studies have examined the possible interactions
between CB1 and CB2 receptors despite the fact that they have
overlapping expression and that the two receptors have been
shown to impact similar cellular processes. Here we report that
CB1 and CB2 receptors can form functional heteromers in
transfected cells and in a variety of brain tissues. Heteromer
formation leads to a negative cross-talk between receptor ago-
nists and antagonists, suggesting an additional level of molecu-
lar regulation between the two receptors.
MATERIALS ANDMETHODS
Fusion Proteins and Expression Vectors—The human cDNA
for the CB1, CB2, and dopamine D4.4 receptors cloned in
pcDNA3.1 were amplified without their stop codons using
sense and antisense primers harboring either unique EcoRI and
BamHI sites (CB1R, CB2R) orXhoI and EcoRI (D4.4R). The frag-
ments were then subcloned to be in frame with Rluc into the
EcoRI and BamHI restriction sites of an Rluc-expressing vector
(pRluc-N1, PerkinElmer) or with enhanced YFP into the EcoRI
and BamHI (CB1R, CB2R) or XhoI and EcoRI restriction sites of
an enhanced YFP-expressing vector (EYFP-N1; enhanced yel-
low variant of GFP; Clontech) to give the plasmids that express
CB1, CB2, or D4.4 receptors fused to Rluc or YFP on the C-ter-
minal end of the receptor (CB2R-Rluc, CB2R-YFP, CB1R-YFP,
or D4R-YFP). Expression of constructs was tested by confocal
microscopy, and the receptor functionality was tested by the
ERK1/2 activation pathway (see “Results”).
Cell Line Cultures and Transfection—Human embryonic
kidney (HEK-293T), human neuroblastoma SH-SY5Y, and
neuroblastoma and glioma hybrid NG108-15 cell lines were
grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 100 units/ml penicillin/streptomycin and 10%
(v/v) heat-inactivated fetal bovine serum (FBS). Other supple-
ments were 2 mM L-glutamine for HEK-293T and SH-SY5Y
cells, 1 mM sodium pyruvate for SH-SY5Y cells, and 100 M
hypoxanthine, 0.02 M aminopterin, 16 M thymidine (HAT
supplement) for NG108-15 cells. The human neuroblastoma
SK-N-MC cells were grown in minimum essential medium
supplemented with 2 mM L-glutamine, 100 IU/ml penicillin/
streptomycin, 1 mM sodium pyruvate, and 10% (v/v) heat-inac-
tivated FBS. All supplements were from Invitrogen. Cells were
maintained at 37 °C in a humidified atmosphere of 5% CO2 and
were passaged when they were 80–90% confluent (i.e. approx-
imately twice a week).
HEK-293T or SH-SY5Y cells were transiently transfected
with the corresponding fusion protein cDNA by the ramified
PEI (Sigma) method. Cells were incubated (4 h) with the corre-
sponding cDNA together with ramified PEI (5 ml of 10 mM PEI
for each mg of cDNA) and 150 mM NaCl in a serum-starved
medium. After 4 h, the medium was changed to a fresh com-
plete culturemedium. 72 h after transfection, cells werewashed
twice in quick succession in Hanks’ balanced salt solution (137
mM NaCl, 5 mM KCl, 0.34 mM Na2HPO412H2O, 0.44 mM
KH2PO4, 1.26 mM CaCl22H2O, 0.4 mM MgSO47H2O, 0.5 mM
MgCl2, 10mMHEPES, pH7.4) supplementedwith 0.1% glucose
(w/v), detached by gently pipetting, and resuspended in the
same buffer. To control the cell number, sample protein con-
centration was determined using a Bradford assay kit (Bio-Rad)
using bovine serum albumin dilutions as standards.
Primary Cultures of Rat Pinealocytes—Male Sprague-Dawley
rats (3month old,350 g), receivingwater and food ad libitum,
were obtained from the animal facility of the Faculty of Biology
(University of Barcelona). 4% isoflurane (2-chloro-2-(difluoro-
methoxy)-1,1,1-trifluoroethane)-anesthetized animals were
killed by decapitation at 20:00 h (after the light period), and
pineal glands were immediately dissected. All procedures were
approved by the Catalan Ethical Committee for Animal Use
(CEAA/DMAH 4049 and 5664). Pinealocytes were prepared
from rat pineal glands as described previously by da Silveira
Cruz-Machado et al. (51). Briefly, pinealocytes were obtained
by trypsinization (0.25%, 37 °C, 15min) followed bymechanical
dispersion in the presence of fetal bovine serum. Cells were
pelleted and resuspended in defined culture medium BGJb
(Invitrogen) supplemented with 10% (v/v) fetal bovine serum
(heat-inactivated), 100 units/ml penicillin/streptomycin (pH
7.4). The total number of cells and fractional survival was esti-
mated by trypan blue exclusion. Cells (200,000 cells/well) were
plated on polylysine-coated 6-well chamber plates and main-
tained at 37 °C, 5% CO2 for 48 h prior to use.
Rat Brain Slice Preparation—Rats were decapitated with a
guillotine, and the brains were rapidly removed and placed in
ice-cold oxygenated (O2/CO2, 95%/5%) Krebs-HCO3 buffer
(124 mM NaCl, 4 mM KCl, 1.25 mM NaH2PO4, 1.5 mM MgCl2,
1.5 mM CaCl2, 10 mM glucose, and 26 mM NaHCO3, pH 7.4).
The brains were sliced at 4 °C in a brain matrix (Zivic Instru-
ments, Pittsburgh, PA) into 0.5-mm coronal slices. Slices were
kept at 4 °C in Krebs-HCO3 buffer during the dissection of the
nucleus accumbens and the globus pallidus. For signaling
experiments, each slice was transferred into an incubation tube
containing 1 ml of ice-cold Krebs-HCO3 buffer, and the
ERK1/2 phosphorylation was determined as described below.
For proximity ligation assays, slices were fixed with 4% parafor-
maldehyde solution for 1 h at room temperature with gentle
agitation. The sliceswere thenwashed inTBS (50mMTris-HCl,
0.9% NaCl, pH 7.8) and treated for 5 min with 1% Na2BH4
dissolved in TBS, followed by successive TBS washes until all
Na2BH4 was eliminated. Finally, the slices were cryopreserved
in a 30% sucrose solution overnight at 4 °C and stored at20 °C
4 The abbreviations used are: GPCR, G protein-coupled receptor; PLA, prox-
imity ligation assay(s); BRET, bioluminescence resonance energy transfer;
ANOVA, analysis of variance; ACEA, arachidonyl-2-chloroethylamide.
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until sectioning. 15-m-thick slices were cut on a freezing cryo-
stat (Leica Jung CM-3000) and mounted on slide glass. Slices
were thawed at 4 °C, washed in TBS, and rockedwith the block-
ing solution (Olink Bioscience, Uppsala, Sweden) for 1 h at
37 °C in a humidified atmosphere.
In Situ Proximity Ligation Assay (PLA)—Primary cultures of
pinealocytes or SH-SY5Y cells transfected or not with 3 g of
cDNA corresponding to CB2R-HA (Missouri S&T Resource
Center), were fixed in 4% paraformaldehyde for 15 min and
washed with phosphate-buffered saline (PBS) containing 20
mM glycine to quench the aldehyde groups. After permeabiliza-
tionwith PBS-glycine containing 0.05%TritonX-100 for 5min,
cells were incubated for 1 h at room temperature with PBS
containing 1% bovine serum albumin. Rat nucleus accumbens
slices were obtained as described above. The receptor-receptor
molecular interaction in these samples was detected using the
Duolink II in situ PLA detection kit (Olink Bioscience). To
detect heteromers in pinealocytes or in nucleus accumbens
slices, the direct PLA-linked primary antibodies were used. The
rabbit anti-CB1 receptor antibody (Thermo Scientific) was
linked to a plus PLA probe, and the rabbit anti-CB2 receptor
antibody (Cayman Chemical, Ann Arbor, MI) was linked to a
minus PLA probe following the instructions of the supplier.
After a 1-h incubation at 37 °C with the blocking solution in a
preheated humidity chamber, pinealocytes or slices were incu-
bated overnight with these PLA probe-linked antibodies
(1:1000) at 4 °C. After washing with wash buffer at room tem-
perature, samples were processed for ligation, amplification,
and detection as described by the manufacturer. As negative
controls, pinealocytes or slices were incubated overnight with
the plus PLA probe-linked rabbit anti-CB1 receptor antibody
and a goat anti-D4 receptor primary antibody (1:500; Santa
Cruz Biotechnology) at 4 °C, followed by an incubation (2 h,
37 °C) in a preheated humidity chamber with Duolink II minus
PLA probe anti-goat diluted in the antibody diluent. To detect
heteromers in SH-SY5Y cells, transfected or non-transfected
(as negative controls) cells were incubated (1 h, 37 °C) with the
blocking solution in a preheated humidity chamber and then
incubated overnight with the primary antibodies: rabbit anti-
CB1 receptor antibody (1:1000; Thermo Scientific) and mouse
monoclonal anti-HA tag antibody (1:1000; Abcam, Cambridge,
UK) in the antibody diluent medium. SH-SY5Y cells were
washed with washing buffer at room temperature and incu-
bated (2 h, 37 °C) in a preheated humidity chamber with PLA
probes detecting rabbit or mouse antibodies (Duolink II plus
PLA probe anti-rabbit and Duolink II minus PLA probe anti-
mouse) and processed as described above. Samples were
mounted using themountingmediumwithDAPI and observed
in a Leica SP2 confocal microscope (Leica Microsystems,
Mannheim, Germany).
Immunostaining—After 72 h of transfection,HEK-292T cells
were fixed in 4% paraformaldehyde for 15min andwashedwith
PBS containing 20 mM glycine to quench the aldehyde groups.
After permeabilization with PBS-glycine containing 0.05% Tri-
ton X-100 for 5 min, cells were incubated with PBS containing
1% bovine serum albumin. After 1 h at room temperature, pro-
tein-Rlucwas labeledwith the primarymousemonoclonal anti-
Rluc antibody (1:100; Chemicon, Billerica,MA) for 1 h, washed,
and stained with the secondary antibody Cy3 donkey anti-
mouse (1:200; Jackson Immunoresearch Laboratories, West
Grove, PA). Protein-YFPwas detected by its fluorescence prop-
erties. The sampleswere rinsed several times andmountedwith
a medium suitable for immunofluorescence (30%Mowiol, Cal-
biochem). The samples were observed in a Leica SP2 confocal
microscope.
RT-PCR—Total cellular RNA was isolated from HEK-293T,
SH-SY5Y, SK-N-MC, or NG108-15 cells using the QuickPrep
total RNA extraction kit (Amersham Biosciences) or from
Macaca fascicularis spleen usingTRIzol reagent (Invitrogen) as
described previously (38). Total RNA (1 g) was reverse-tran-
scribed by random priming using Moloney murine leukemia
virus reverse transcriptase, RNase H minus, and point mutant,
following the protocol of two-step RT-PCR provided by Pro-
mega (Madison, WI). The resulting single-stranded cDNA was
used to perform PCR amplification for the CB1 and CB2 recep-
tors and GAPDH as an internal control of PCR technique using
TaqDNA polymerase (Promega). Common primers to amplify
human and rat cDNAwere used. Primers to amplify CB1Rwere
5-TGGGCAGCCTGTTCCTCAC-3 (forward) and 5-CAT-
GCGGGCTTGGTC-3 (reverse). Primers to amplify CB2R
were 5- CGTGGCTGTGCTCTATCTGA-3 (forward) and
5-AGCCAGCTCAGCAGGTAGTC-3 (reverse). To amplify
GAPDH, the primers used were 5-CATCCTGCACCAC-
CAACTGCTTAG-3 (forward) and 5-GCCTGCTTCAC-
CACCTTCTTGATG-3 (reverse). RNA without reverse tran-
scriptions did not yield any amplicons, indicating that therewas
no genomic DNA contamination.
Bioluminescence Resonance Energy Transfer (BRET) Assays—
HEK-293T cells were transiently co-transfected with the indi-
cated amounts of plasmid cDNAs corresponding to the indi-
cated fusion proteins (see Fig. 1 legend). To quantify receptor
fluorescence expression, cells (20 g of protein) were distrib-
uted in 96-well microplates (black plates with a transparent
bottom; Porvair (King’s Lynn, UK)), and fluorescence was read
in a FluoStar Optima fluorimeter (BMG Labtechnologies,
Offenburg, Germany) equipped with a high energy xenon flash
lamp, using a 10-nm bandwidth excitation filter at a reading of
400 nm. Receptor fluorescence expression was determined as
the fluorescence of the sample minus the fluorescence of cells
expressing protein-Rluc alone. For BRET measurements, the
equivalent of 20g of protein was distributed in 96-well micro-
plates (Corning 3600, white plates; Sigma), and 5 M coelen-
terazine H (Molecular Probes, Inc., Eugene, OR) was added.
After 1 min of adding coelenterazine H, the readings were col-
lected using a Mithras LB 940 (Berthold, Bad Wildbad, Ger-
many), which allows the integration of the signals detected in
the short wavelength filter at 485 nm (440–500 nm) and the
long wavelength filter at 530 nm (510–590 nm). To quantify
receptor-Rluc expression luminescence, readings were per-
formed 10 min after the addition of 5 M coelenterazine H.
Cells expressing BRET donors alone were used to determine
background.Thenet BRET is defined as (longwavelength emis-
sion/short wavelength emission)Cf, whereCf corresponds to
long wavelength emission/short wavelength emission for the
Rluc construct expressed alone in the same experiment. BRET
curves were fitted by using a non-linear regression equation,
CB1 and CB2 Receptors FormHeteromers
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assuming a single phase with GraphPad Prism software (San
Diego, CA)
ERK1/2 and Akt/PKB Phosphorylation Assays—Each globus
pallidus slice, obtained as described above, was transferred into
an incubation tube containing 1 ml of ice-cold Krebs-HCO3
buffer, and the temperature was raised to 23 °C. After 30 min,
the medium was replaced by 2 ml of Krebs-HCO3 buffer
(23 °C) and was incubated under constant oxygenation (O2/
CO2, 95%/5%) at 30 °C for 4–5h in anEppendorf Thermomixer
(5 Prime, Inc., Boulder, CO). The medium was replaced by 200
l of freshKrebs-HCO3 buffer and incubated for 30min before
the addition of the desired concentrations of ligands. After the
indicated incubation period, the solution was discarded, and
slices were frozen on dry ice and stored at 80 °C until use.
Transfected or non-transfected SH-SY5Y cells were cultured in
serum-free medium for 16 h before the addition of any agent.
Cells were treated or not with the indicated agonists for the
indicated time. At the end of the incubation period, cells were
rinsed with ice-cold phosphate-buffered saline. Cells or slices
were lysed by the addition of 500 l of ice-cold lysis buffer (50
mMTris-HCl, pH 7.4, 50mMNaF, 150mMNaCl, 45mM-glyc-
erophosphate, 1%TritonX-100, 20Mphenyl-arsine oxide, 0.4
mM NaVO4, and protease inhibitor mixture). The cellular
debris was removed by centrifugation at 13,000 g for 5min at
4 °C, and the protein was quantified by the bicinchoninic acid
method using bovine serum albumin dilutions as a standard.
Equivalent amounts of protein (10 g) were separated by elec-
trophoresis on a denaturing 7.5% SDS-polyacrylamide gel and
transferred onto a PVDF-FL membrane. Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE) was then added, and
themembrane was rocked for 90min. Themembrane was then
incubated overnight with a mixture of a rabbit anti-phospho-
Ser473 Akt antibody (1:2500; Signalway Antibody) to test the
Akt phosphorylation ormouse anti-phospho-ERK1/2 antibody
(1:2500; Sigma) to test ERK1/2 phosphorylation. As a control of
the amount of protein loaded, rabbit anti-ERK1/2 antibody that
recognizes both phosphorylated and non-phosphorylated
ERK1/2 (1:40,000; Sigma) was used. Bands were visualized by
the addition of IRDye 680 (anti-rabbit) antibody (1:10,000;
Sigma) or IRDye 800 (anti-mouse) antibody (1:10,000; Sigma)
or amixture of both for 1 h and scanned by theOdyssey infrared
scanner (LI-COR Biosciences). Band densities were quantified
using the scanner software and exported to Excel (Microsoft,
Redmond,WA). The level of phosphorylated proteins was nor-
malized for differences in loading using the total ERK1/2 pro-
tein band intensities.
Evaluation of Neurite Outgrowth—SH-SY5Y cells seeded in
10-mm coated glass coverslips were transfected or not with 3
g of cDNA corresponding to CB2R-YFP. 48 h post-transfec-
tion, cells were incubated for 24 h in serum-free growing
medium in the absence or presence of 10 M retinoic acid, 100
nM ACEA, or 50 nM JWH 133 (all from Tocris, Bristol, UK)
alone or in combination. Cells were washed three times with
PBS, fixed in 4% paraformaldehyde for 15 min, washed with
PBS containing 20 mM glycine, permeabilized for 5 min
with PBS-glycine buffer containing 0.05% Triton X-100, and
blocked with PBS containing 1% BSA for 1 h at room tempera-
ture. Cells were labeled for 1 h with the primary mouse anti-
MAP2 antibody (1:200; Calbiochem). Subsequently, cells were
washed and stained with the secondary antibody, Cy3-conju-
gated affinity-purified donkey anti-mouse IgG (1:200 dilution;
Jackson ImmunoResearch Laboratories), and nuclear staining
was performed with Hoechst (1:1000, 1 mg/ml; Sigma). Cover-
slips were rinsed for 5 min in PBS containing 1% BSA and for 5
min in PBS-glycine buffer andmountedwithMowiolmounting
medium. Confocal microscope observations were made with a
Leica TCS SP2 microscope with a 40 objective. Cell bodies
and neurites present in 8–12 randomly selected fields were
measured in each experiment using ImageJ software. Cells were
considered to be differentiated if they had at least one process
longer than the cell body, whichwould be regarded as a neurite.
The results are expressed as the percentage of differentiated
cells versus the total cell number in non-transfected cells or
versus CB2R-YFP-expressing cells (detected by its own fluores-
cence) in transfected cells. At least three independent experi-
ments were conducted for each treatment.
RESULTS
CB2Receptors FormHeteromers withCB1 Receptors in Trans-
fectedCells—Avariety ofGPCRs, includingCB1 receptors, have
been reported to be expressed as homomers and form hetero-
mers with other GPCRs (43, 45, 49, 52), but it is not known
whether CB2 and CB1 receptors can form heteromers. To test
this, the BRET technique was used. The BRET technique
requires the use of fusion proteins consisting of CB2R-Rluc,
CB1R-YFP, and CB2R-YFP. Prior to the BRET experiments, we
first confirmed that the fusion of Rluc or YFP to CB2 or CB1
receptors did not modify receptor function, as determined by
ERK1/2 phosphorylation assays (Fig. 1A). In addition, we con-
firmed that the subcellular localization of the fusion proteins
was indeed in the cell membrane, showing a high degree of
colocalization when CB2R-Rluc and CB2R-YFP or CB2R-Rluc
andCB1R-YFPwere co-expressed (Fig. 1B). To test the ability of
CB1 and CB2 receptors to form heteromers, BRET measure-
ments were performed in transiently co-transfectedHEK-293T
cells using a constant amount of cDNAcorresponding toCB2R-
Rluc and increasing amounts of cDNA corresponding to CB1R-
YFP. As can be seen in Fig. 1C, the BRET signal increased as a
hyperbolic function of the amount of the CB1R-YFP expressed,
reaching an asymptote. From the saturation curve, a BRETmax
of 33 1 milli BRET units (mBU) and a BRET50 of 8 2 were
calculated. The specificity of this interaction was demonstrated
by comparing the BRET saturation curve with the low and lin-
ear BRET obtained for the negative control constituted by
CB1R-Rluc and D4R-YFP (Fig. 1C). These results indicate that
CB1 andCB2 receptors formheteromers in co-transfected cells.
CB1 and CB2 Receptors FormHeteromers in SH-SY5YNeuro-
blastoma Cells—Knowing that CB1 and CB2 receptors form
heteromers in HEK-293T transfected cells, we investigated
whether they can formheteromers in a neuronal cellmodel.We
first determined the endogenous receptor expression in differ-
ent neuroblastoma cell lines. As shown in Fig. 2A, all neuroblas-
toma cells tested expressed the mRNA corresponding to CB1
receptor, but they did not express the mRNA corresponding to
CB2 receptor. From these results, human SH-SY5Y neuroblas-
toma cells were selected. Non-transfected cells were used as
CB1 and CB2 Receptors FormHeteromers
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CB1 receptor-expressing neuroblastoma cells, whereas
SH-SY5Y cells transfected with HA tagged CB2 receptor were
used as CB1 receptor- and CB2 receptor-expressing cells. The
BRET technique is a powerful approach for looking at receptor
interactions in co-transfected cells, but BRET cannot be easily
applied in native cells endogenously expressing one or both
receptors. To solve this, other direct and indirect methods can
be used. Here we sought to determine if the endogenous
expressed CB1 and transfected CB2 receptors could also form
heteromers in a neuronal cell model. To do this, we employed
the PLA, which is used to detect protein interactions. This
direct method requires that both receptors be close enough to
allow the two different antibody-DNA probes to be able to
ligate (17 nm) (53, 54). If the receptors are within sufficient
proximity, a punctate fluorescent signal can be detected by con-
focal microscopy diagrammed in Fig. 2B. For these experi-
ments, two different and specific primary antibodies directed
against each of the two receptors were used. One was the well
known commercial mouse anti-HA antibody to detect the HA-
labeledCB2 receptor, and the other was a rabbit anti CB1 recep-
tor antibody. The specificity of this last antibody was tested in
CB1R-YFP- or CB2R-YFP-transfected HEK-293T cells (Fig.
2C). Colocalization of fluorescence due to YFP with the anti-
CB1 receptor antibody staining was detected in CB1R-YFP-
transfected cells but not in CB2R-YFP-transfected cells, and a
lack of antibody-promoted staining was observed in non-trans-
fected cells (cells that do not show fluorescence) (Fig. 2C).
Using these antibodies in PLA experiments, the CB1-CB2
FIGURE 1. CB2 receptors form heteromers with CB1 receptors in transfected cells. A, the functionality of fusion proteins in HEK-293T cells transfectedwith
1.5 g of cDNA corresponding to CB1 receptor, CB2 receptor, CB2R-YFP, CB1R-YFP, or CB2R-Rluc. 72 h post-transfected cells expressing CB2R, CB2R-YFP, or
CB2R-Rlucwere treated for 7minwith vehicle (basal) orwith JWH133 (100nM), and cells expressingCB1RorCB1R-YFPwere treated for 7minwith vehicle (basal)
or with CP 55940 (500 nM), and ERK1/2 phosphorylation was determined. Results (means  S.E. (error bars) of four different experiments performed in
duplicate) represent -foldoverbasal. Significantdifferenceswere analyzedbyone-wayANOVA followedbyDunnett’smultiple comparisonpost hoc test (*,p
0.05; **, p  0.01; ***, p  0.001 compared with basal). Above is a representative Western blot. B, confocal microscopy images of cells transfected with the
plasmid corresponding to CB2R-YFP (1.5 g), CB2R-Rluc (0.5 g), or CB1R-YFP (1.5 g) alone (top panels) or in combination (middle panels for CB2R-Rluc and
CB2R-YFP and lower panels for CB2R-Rluc and CB1R-YFP). Proteins were identified by fluorescence or by immunocytochemistry as indicated under “Materials
andMethods.” Colocalization is shown in yellow inmergepanels. Scale bars, 10m.C, BRET saturationexperiments showingCB1-CB2 receptor heteromerization
were performed as described under “Materials andMethods” using cells transfectedwith 0.2g of cDNA corresponding to CB2R-Rluc and increasing amounts
of cDNA (0–4gof cDNA) corresponding toCB1R-YFP (circles). As anegative control, cellswere also transfectedwith cDNAcorresponding toCB1R-Rluc (0.2g)
anddopamineD4R-YFP (0–4gof cDNA) (triangles). Both fluorescence and luminescence for each sampleweremeasuredbefore every experiment to confirm
similar donor expressions (100,000 bioluminescence units) while monitoring the increase in acceptor expression (100–20,000 net fluorescence units). The
relative amount of BRET is given as the ratio between the net fluorescence of the acceptor (YFP-YFP0), and the luciferase activity of the donor (Rluc). BRET data
are expressed as means S.E. of four different experiments grouped as a function of the amount of BRET acceptor.mBU, milli BRET units.
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receptor heteromer expression in SH-SY5Y cells was demon-
strated by punctuate fluorescent signal detected by confocal
microscopy after excitation at 624 nm. This pattern was
observed in CB2 receptor-expressing cells, whereas no signal
was detected in non-transfected cells used as a negative control
(Fig. 2D).
CB1-CB2 Receptor Heteromers Are Expressed in Rat Brain—
To gain more insight about the physiological relevance of CB1-
CB2 receptor heteromers, we next investigated the expression
of these heteromers in the rat brain taking advantage of the PLA
approach used above. CB1 is the most abundant GPCR in the
brain (55). Although CB2 receptor expression is much lower,
sometimes even undetectable, it is also known to be present in
different brain areas, impacting endocannabinoid signaling and
colocalizing with CB1 receptors (32, 34, 36, 37, 56–59).
Recently, it has been shown that both CB1 and CB2 receptors
are co-expressed in the pineal gland, where they may be
involved in the control of pineal physiology (57), and in the
nucleus accumbens, where CB2 receptor controls cocaine
intake (59). Despite evidence of their co-expression, nothing is
known about CB1 and CB2 receptor molecular interactions in
the brain. Here we determined the expression of CB1-CB2
receptor heteromers in rat pinealocytes and nucleus accum-
bens by PLA. We used the rabbit anti-CB1 receptor antibody
described above and a rabbit anti-CB2 receptor antibody that is
specific for the CB2 receptor, as previously demonstrated (57).
Both antibodies were used directly linked to the PLA DNA
probes, as described under “Materials and Methods.” PLA
FIGURE 2.CB1-CB2 receptor heteromers in neuroblastoma cells.A, CB1 andCB2 receptormRNAexpression in different neuroblastoma cellswas analyzedby
RT-PCR using total RNA from SH-SY5Y, SK-N-MC, or NG108-15 neuroblastoma cells and specific common primers for the human and rat CB2 and CB1 receptors
or GAPDH as internal control ofmRNA expression. As positive controls for the CB2 receptor expression, total RNAs fromhuman spleen or HEK-293T cells stably
expressing human CB2 receptors (HEK CB2) were used, and RNAs from HEK-293T cells (HEK-293T) or primers without RNA (control) were included as negative
controls. B, a schematic representation of the PLA technology is shown. Receptors were recognized by primary antibodies and secondary antibodies linked to
different DNA chains, one plus and one minus. If the two receptors are close enough, the two different antibody-DNA probes are able to ligate. Following an
amplification process, the presence of fluorescently tagged nucleotides allows detection of a punctuate fluorescent signal by confocal microscopy. C, to test
the specificity of rabbit anti-CB1 receptor primary antibody, HEK-293T cells were transfectedwith CB1R-YFP (1.5gof plasmid) (top panels) or CB2R-YFP (1.5g
of plasmid) (bottompanels), and immunocytochemistrywasperformedwith rabbit anti-CB1R, as indicatedunder “Materials andMethods.” CB1 receptor- or CB2
receptor-expressing cellswere identifiedby their own fluorescence, and cell nucleiwere stainedwithHoechst (blue). Colocalization inmerged images is shown
in yellow. Scale bars, 10m.D, PLA in SH-SY5Y cells transfectedwith CB2R-HA (3g of plasmid) (top panels) or without transfection (vehicle; bottom panel). Red
spots in three different fields from independent experiments with CB2 receptor-expressing cells (top panels) but not in non-transfected cells (bottom panel)
indicate the CB1-CB2 receptor heteromer expression. Scale bars, 20 m.
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experiments were performed with pinealocytes obtained from
rat pineal glands extracted from a rat sacrificed at 20 h (after the
light period), when the expression of CB1 and CB2 receptors is
more equilibrated (57), and with rat nucleus accumbens slices
obtained as indicated under “Materials andMethods.” CB1-CB2
receptor heteromers in the primary cultures or in the slices
were visualized as red spots in pinealocytes (Fig. 3A) or neurons
(Fig. 3B) stained with Hoechst. Because CB1 and dopamine D4
receptors do not form heteromers in BRET experiments (see
Fig. 1C) we considered this pair as the negative control and
performed the same assay using the PLA DNA probe-linked
anti-CB1 receptor antibody described above and a goat anti-
body against dopamine D4 receptor plus a goat secondary anti-
body linked to the correspondingPLADNAprobe (Fig. 3,C and
D). A quantification of cells containing one or more red spots
versus total cells (blue nucleus) and the ratio r (number of red
spots/total cells) were determined in eight fields from three
different experiments. 84% of pinealocytes expressed CB1-CB2
receptor heteromers with r 1.48, in contrast with the 24% of
positive cells with r 0.3 detected in the negative control (Fig.
3E). Analogously 51% of nucleus accumbens cells (r  2.11)
expressed CB1-CB2 receptor heteromers, in contrast with 3%
cells (r 0.04) detected for the negative control (Fig. 3F). These
results indicate that CB1-CB2 receptor heteromers are
expressed in rat pinealocytes and in rat nucleus accumbens.
Characterization of CB1-CB2 Receptor Heteromer Signaling—
Acommon and often essential attribute of receptor heteromers
is the ability to modify the downstream signaling versus the
single constituent receptors. This type of receptor-receptor
interaction has been observed for several receptor heteromers
(60, 61). Because cannabinoid receptors have been previously
described to be coupled to Akt/PKB protein activation in dif-
ferent cell types (40, 41, 62), we first investigated whether there
were changes in Akt/PKB (Ser-473 Akt phosphorylation) sig-
naling when heteromers were co-stimulated with both agonists
or blocked with antagonists in SH-SY5Y neuronal cells. Non-
transfected cells were used as CB1 receptor-expressing neuro-
blastoma cells, and cells transfected with CB2R-YFP were used
as CB1- and CB2 receptor-expressing cells. Treatment with 100
nM CB1 receptor agonist ACEA induced Akt/PKB phosphory-
lation in both non-transfected and transfected cells (Fig. 4, A
and B), and the CB2 receptor agonist JWH 133 induced Akt/
PKB phosphorylation only in transfected cells (Fig. 4, A and B).
Furthermore, JWH 133-induced Akt/PKB signaling was signif-
icantly diminished when cells expressing both receptors were
co-stimulatedwithACEA and JWH133 (Fig. 4,B andD). These
results indicate that a negative cross-talk exists between CB1
and CB2 receptors in Akt/PKB phosphorylation signaling.
These results are not due to a change in the time in which the
signaling peaks because differences were not observed in time-
FIGURE 3. CB1-CB2 receptor heteromers in rat brain. The PLA was performed using primary cultures of rat pinealocytes (A and C) or rat nucleus accumbens
slices (B and D). Pinealocytes (A) or slices (B) were treated with rabbit CB1 receptor and CB2 receptor primary antibodies directly linked to plus and minus PLA
probes (see “Materials and Methods”). CB1-CB2 receptor heteromers were visualized as red spots around Hoechst-stained nuclei (A and B). Negative controls
were performedwith pinealocytes (C) or slices (D) treatedwith plus PLAprobe-linked rabbit anti-CB1 receptor andwith primary goat anti-D4 receptor detected
with a minus PLA probe-linked secondary goat antibody. Scale bars, 20m. The percentage of pinealocytes (E) or nucleus accumbens neurons (F) containing
one or more red spots versus total cells (blue nucleus) is given as well as r (number of red spots/total cells) values (E and F) from eight fields in three different
experiments. Error bars, S.E.
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response curves when cells were activated with one or both
agonists (Fig. 4C). It is important to point out that all ligands
were first chosen based on theirKI value (KI 1.4 nM for ACEA
1400-fold selective for CB1 receptor; KI  3.4 nM for JWH
133, 200-fold selective for CB2 receptor) and following a
dose-response curve for Akt activation, where the lowest con-
centration that provided specific receptor signaling was chosen
as the working concentration.
Looking at the effect of CB1 and CB2 receptor antagonists,
the 100 nM ACEA-induced Akt/PKB phosphorylation was not
significantly modified when non-transfected cells were pre-
treated with 500 nM AM630, a 165-fold selective CB2 receptor
antagonist over CB1 receptor (63) (Fig. 4A), but it was com-
pletely counteracted when non-transfected and transfected
cells were pretreated with 200 nM AM251, a 306-fold selective
CB1 receptor antagonist over CB2 receptor (64), as expected for
FIGURE 4.Agonist and antagonist interactions betweenCB1 andCB2 receptors onAkt/PKBphosphorylation (P-AKT) in SH-SY5Yneuroblastoma cells.
SH-SY5Y cells (A) or SH-SY5Y cells transfectedwith 3g of cDNA corresponding to CB2R-YFP (B–D) were used. In A and B, cells were treated for 20min. with the
agonists ACEA (100 nM) or JWH 133 (50 nM) alone or in combination or pretreated for 30 min with the antagonist AM630 (500 nM) or AM251 (200 nM) prior to
agonist treatment. Akt/PKB phosphorylation was measured as indicated under “Materials and Methods.” Results (means  S.E. (error bars) of four different
experiments performed in duplicate) are expressed as -fold over basal (non-stimulated cells). Significant differences were analyzed by a one-way ANOVA
followed by post-hoc Bonferroni’s tests (*, p 0.05; **, p 0.01; ***, p 0.001 compared with basal. #, p 0.05; ##, p 0.01; ###, p 0.001 compared with
treatedwithACEAalone. &,p0.05; &&,p0.01; &&&,p0.001 comparedwith treatedwith JWH133 alone).C, time-response curves of SH-SY5Y cells treated
for the indicated times with 100 nM ACEA (white bars) or 50 nM JWH 133 (black bars) alone or in combination (gray bars). Results (means S.E. of four different
experiments performed in duplicate) are expressed as -fold over basal (non-stimulated cells). Significant differences were analyzed by a one-way ANOVA
followed by post hoc Bonferroni’s tests (***, p 0.001 comparedwith treated onlywith JWH133. ##, p 0.01; ###, p 0.001 comparedwith treated onlywith
ACEA alone).D, effect of 30min 500 nM AM630 or 200 nM AM251 antagonist pretreatment in SH-SY5Y cells co-stimulated for 20min with 100 nM ACEA and 50
nM JWH133. Results (means S.E. of four different experiments performed in duplicate) are expressed as -fold over basal (non-stimulated cells). No significant
differences were detected in D.
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specific CB1-agonistic interaction (Fig. 4, A and B). However,
interestingly, ACEA-inducedAkt/PKBphosphorylation in cells
expressing both receptors was also significantly prevented by
pretreatment with AM630 (Fig. 4B). Moreover, treatment with
50 nM JWH 133, a 200-fold selective CB2 receptor agonist over
CB1 receptor (65), did not induce Akt/PKB phosphorylation in
non-transfected SH-SY5Y cells due to the lack of CB2 receptor
expression in these cells (Fig. 4A) but was able to induce Akt/
PKBphosphorylation in cells expressingCB1 andCB2 receptors
(Fig. 4B). JWH133-inducedphosphorylationwas blockedwhen
cells expressing both cannabinoid receptors were pretreated
with AM630, as expected for a specific CB2 receptor agonist,
but was also prevented when cells expressing both receptors
were pretreated with the CB1 receptor antagonist AM251.
These results indicate that a bidirectional cross-antagonism
exists between CB1 and CB2 receptors in Akt/PKB phosphory-
lation signaling. We used this heteromer characteristic to fur-
ther test for the expression of CB1-CB2 receptor heteromers in
rat brains. We selected globus pallidus slices for these experi-
ments because it has been described that globus pallidus
expresses a high amount of CB2 receptor (38). The Akt/PKB
and ERK1/2 phosphorylation was determined in slices as indi-
cated under “Materials and Methods.” CB1 and CB2 receptors
were poorly coupled to Akt/PKB phosphorylation in the globus
pallidus (results not shown), but the activation of both recep-
tors increased ERK1/2 phosphorylation (Fig. 5). The JWH 133
agonist-induced ERK1/2 phosphorylation was blocked by
AM630, as expected for a specific CB2 receptor antagonist, but
this antagonist was also able to block the ERK1/2 phosphory-
lation induced by the CB1 receptor agonist ACEA, showing a
cross-antagonism. These results strongly suggest that CB1-CB2
receptor heteromers may likely be expressed in the globus
pallidus.
Functional Characterization of CB1-CB2 Receptor Hetero-
mers on Neurite Outgrowth—Because the endocannabinoid
signaling pathway is involved in brain development and neural
cell differentiation (66–68) and because activation of PI3K/Akt
signaling is involved in neural differentiation of SH-SY5Y cells
(69), we investigated the role of CB1-CB2 receptor heteromers
on neuritogenesis in our SH-SY5Y neuronal cell model. Again,
non-transfected cells were used as CB1 receptor-expressing
neuroblastoma cells, and cells transfected with CB2R-YFPwere
used as CB1 and CB2 receptor-expressing cells. The human
neuroblastoma cell line SH-SY5Y is a well characterized model
system to study neuronal differentiation in vitro. These cells
develop long extensions and express several neuronal markers
when treated with different agents, including retinoic acid or
phorbol esters (70). SH-SY5Y cells reduce their rate of growth
and initialize differentiation, adopting a neuronal phenotype
when exposed to 10 M retinoic acid (71, 72). This reagent was
therefore used as a control treatment for neuritogenesis (Fig. 6).
The effect of CB1 and CB2 receptor agonists on neuritogenesis
was analyzed by confocal microscopy, by quantifying neuritic
processes in cells stained with an antibody against themicrotu-
bule-associated proteinMAP-2 (anti-MAP-2). Treatment with
ACEA induced, in both non-transfected (Fig. 6A) and trans-
fected (Fig. 6B) SH-SY5Y cells, the appearance of neurites to a
moderate extent compared with the effect exerted by retinoic
acid. Treatment with JWH 133, a selective CB2 receptor ago-
nist, did not induce neuritogenesis in non-transfected
SH-SY5Y cells because they do not express CB2 receptor (Fig.
6A), but it induced neuritogenesis in cells expressing CB1 and
CB2 receptors (Fig. 6B). When cells expressing CB1 and CB2
receptors were co-stimulated with JWH 133 and ACEA, the
JWH 133-induced neuritogenesis was diminished (Fig. 6, B and
C), indicating a negative cross-talk betweenCB1 andCB2 recep-
tors in neuroblastoma cell differentiation, a phenomenon that
is similar to the negative cross-talk observed at the Akt/PKB
signaling.
Finally, we evaluated whether the bidirectional cross-antag-
onism observed between CB1 and CB2 receptors in signaling
can also be observed in the cannabinoid receptor-mediated
neuritogenesis. As expected, the CB1 receptor antagonist
AM251, but not the CB2 receptor antagonist AM630, com-
pletely blocked the CB1 receptor agonist ACEA-induced
neuritogenesis in non-transfected SH-SY5Y cells (Fig. 7A).
Interestingly, bothAM251 andAM630were able to prevent the
ACEA-induced or the CB2 receptor agonist JWH 133-induced
FIGURE 5. CB1-CB2 receptor heteromer fingerprint was found in rat glo-
buspallidus.Globus pallidus sliceswere obtained as describedunder “Mate-
rials andMethods” and treated for 10minwith 500 nM JWH 133 or 1MACEA
or pretreated for 20 min with 5 M AM630 antagonist prior to agonist treat-
ment. ERK1/2 phosphorylation (P-ERK 1/2) was determined as described
under “Materials and Methods.” Results (means S.E. (error bars) of two dif-
ferent experiments performed in triplicate) are expressed as -fold over basal
(non-stimulated cells). Significant differences were analyzed by a one-way
ANOVA followed by post hoc Bonferroni’s tests (*, p  0.05 compared with
basal; #, p 0.05 compared with the respective agonist-treated cells). Above
is a representative Western blot.
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neuritogenesis in CB2 receptor-expressing SH-SY5Y cells (Fig.
7B). These results demonstrate the existence of a bidirectional
cross-antagonism in the differentiation process that matches
that observed in the Akt/PKB signaling described above. This
indicates that the antagonist binding to one receptor in the
CB1-CB2 receptor heteromer blocks the functionality of the
entire heteromer.
DISCUSSION
The cannabinoid receptors CB1 and CB2 are increasingly
becoming an important subject for investigation in a variety of
neurological and immunological processes (1, 10–13).
Although it has been described that both receptors can be co-
expressed in the same brain areas (38, 57–59), the relationship
between both receptors at the molecular level is not known.
Among GPCRs, more and more evidence points to an impor-
tant role of heteromer formation between GPCRs on receptor
function modulation (42, 48, 60, 73). However, determination
of the heteromer functional characteristics and, mainly, identi-
fication of heteromers in tissue is often a challenge. Here, we
present evidence of CB2 receptor molecular and functional
interaction with CB1 receptors. Several conclusions can be
drawn from the data. First, CB1 and CB2 receptors can form
heteromers in transfected cells and in a variety of brain tissues,
including pineal gland, nucleus accumbens, and globus palli-
dus. Second, one specific characteristic of CB1-CB2 receptor
heteromers is that of bidirectional cross-antagonism (i.e. the
ability of CB1 receptor antagonists to block the effect of CB2
receptor agonists and, conversely, the ability of CB2 receptor
antagonists to block the effect of CB1 receptor agonists). Third,
agonist co-activation of CB1-CB2 receptor heteromers results
in a negative cross-talk in Akt phosphorylation and neurite
outgrowth.
Although it was known that CB1 receptors are highly
expressed in the central nervous system, it was believed for a
long time that CB2 receptors were restricted to the peripheral
tissues (74). Recently, several studies have shown the expres-
sion of CB2 receptors in brain regions where CB1 receptors are
also expressed (32, 34, 36, 37, 56–59), including the pineal
gland (57), the nucleus accumbens (59), and the globus pallidus
(38). Because the physiological role of the expression of two
different receptors for the same endogenous ligands in the same
brain regions is not obvious, we explored if both receptors are
modulating each other and, for this reason, we first examined
the possibility of direct receptor-receptor interaction by het-
eromerization. The identification of CB1-CB2 receptor hetero-
mers was first performed via BRET, a biophysical technique, in
co-transfected cells and by immunofluorescence using the PLA
FIGURE 6.Agonist interactions between CB1 and CB2 receptors on neurite outgrowth. SH-SY5Y neuroblastoma cells (A) or SH-SY5Y cells transfected with
3g of cDNA corresponding to CB2R-YFP (B and C) were treated for 24 hwith 10M retinoic acid (RA), 100 nMACEA, or 50 nM JWH133 alone or in combination.
Neurite outgrowth was measured as indicated under “Materials and Methods.” Results are expressed as the percentage of differentiated cells versus the total
cell number in non-transfected cells or versus CB2R-YFP expressing cells (detected by their own fluorescence) in transfected cells. Results are expressed as
means S.E. (error bars) of 8–12 fields in three independent experiments. Significant differences between treated and non-treated cells (**, p 0.01; ***, p
0.001) or between co-activated cells compared with cells activated with JWH-133 (##, p 0.01) were determined by a one-way ANOVA followed by post hoc
Bonferroni’s tests. In C, a representative image of cells expressing CB2R-YFP (green) treated as in B is shown. Treated cells were fixed, permeabilized, and
processed for nuclear staining with Hoechst (blue) and for immunocytochemistry with anti-MAP2 antibody (red).
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in a neuronal cellmodel. The definition of a receptor heteromer
is that the heteromer is a macromolecular complex composed
of at least two functional receptor units with biochemical prop-
erties that are demonstrably different from those of its individ-
ual receptors (42). Thus, we focused on the determination of
the functional characteristics of CB1-CB2 receptor heteromers
expressed in neuroblastoma cells. Both cannabinoid receptors
have been shown to signal through the MAPK and Akt/PKB
pathways (41, 62); therefore, we explored the implication of
heteromer formation on these pathways. We first investigated
whether there were changes in Akt/PKB (Ser-473 Akt phos-
phorylation) signaling when heteromers were both co-stimu-
lated with agonists or blocked with antagonists. When neuro-
blastoma cells were co-stimulated with both receptor agonists,
a negative cross-talk was observed betweenCB1 andCB2 recep-
tors in Akt/PKB phosphorylation signaling. It has been
described that activation of PI3K/Akt signaling is involved in
neural differentiation of SH-SY5Y cells (69); according to this,
we observed thatCB1 andCB2 receptor agonists promotedneu-
ritogenesis in our SH-SY5Y neuronal cell model, and, interest-
ingly, we also observed a negative cross-talk in neuritogenesis
when cells were co-stimulated with both receptor agonists.
Thus, both CB1 and CB2 receptors might be negatively modu-
lating each other in signaling pathways where endocannabi-
noids are involved, such as brain development and neural cell
differentiation (66–68), Although these data, coupled with the
BRET and PLA experiments, implicate heteromers in this
receptor modulation, they could also be explained via simple
signaling cross-talk rather than via physical interaction
between receptors. However, the results obtained with the
antagonists clearly show that CB1-CB2 receptor heteromers are
the signaling units. Antagonists, by definition, do not signal;
thus, the fact that a CB1 receptor-specific antagonist can block
CB2 receptor signaling strongly argues against a cross-talk at
the intracellular signaling level. A more likely explanation is
that binding of the antagonist to CB1-CB2 receptor heteromers
leads to a conformational change that reduces CB2 receptor-
inducedAkt/PKB phosphorylation.We found this cross-antag-
onism to be bidirectional in Akt/PKB phosphorylation signal-
ing and in neurite growth.
A question arising from our findings is the following. Are the
CB1-CB2 receptor heteromers indeed expressed in the brain?
We explored this possibility using different approaches. The
cross-antagonism discussed above can be considered as a het-
eromer fingerprint and can be exploited to demonstrate the
expression of CB1-CB2 receptor heteromers in globus pallidus,
a brain region that expresses a high amount of CB2 receptors
(38). CB1 and CB2 receptors were poorly coupled to Akt/PKB
phosphorylation in the rat globus pallidus, but the activation of
both receptors increased ERK1/2 phosphorylation in rat globus
pallidus slices. A clear cross-antagonism was observed for this
signaling pathway, indicating that CB1-CB2 receptor hetero-
mers are expressed in the globus pallidus. A second question
arising from our findings is the following. Can CB1-CB2 recep-
tor heteromers explain some of the reported results in the
brain? Recently it has been described that both CB1 and CB2
receptors are co-expressed in the pineal gland, where they may
be involved in the control of pineal physiology (57). In fact, CB1
and CB2 receptors and the enzymes catalyzing endocannabi-
noid biosynthesis and degradation were expressed in pinealo-
cytes, and immunosignals for the CB2 receptor did not vary
under a 12-h light/12-h dark cycle, whereas CB1 receptor
immunoreaction was significantly reduced at the end of the
light phase, when the expression of both receptors is more bal-
anced (57). We isolated pinealocytes from rat pineal glands
extracted at the end of the light period, and by taking advantage
of the PLA, we demonstrated the expression of CB1-CB2 recep-
tor heteromers in pinealocytes. In the pineal gland, the rhythm
in melatonin biosynthesis is under control of norepinephrine-
mediated regulation of arylalkylamine N-acetyltransferase, the
penultimate enzyme of melatonin biosynthesis (75), and it has
been described that phytocannabinoids like tetrahydrocannab-
inol reduce arylalkylamine N-acetyltransferase activity and
attenuate melatonin biosynthesis in rat pineal glands (76).
Thus, our results favor the hypothesis that through the negative
FIGURE 7. Antagonist interactions between CB1 and CB2 receptors on
neurite outgrowth. SH-SY5Y neuroblastoma cells (A) or SH-SY5Y cell trans-
fectedwith 3gof cDNAcorresponding toCB2R-YFP (B) were treated for 24 h
with 10M retinoic acid (RA), 100nMACEA, or 50nM JWH133or pretreated for
30 min with 500 nM AM630 or AM251 antagonist prior to agonist treatment.
Neurite outgrowth was measured as indicated under “Materials and Meth-
ods.” Results are expressed as thepercentageof differentiated cells versus the
total cell number in non-transfected cells or versus CB2R-YFP-expressing cells
(detected by their own fluorescence) in transfected cells. Results are
expressed as means  S.E. (error bars) of 8–12 fields in three independent
experiments. Significant differences between treated and non-treated cells
(***, p 0.001) or between antagonized cells compared with cells activated
with JWH 133 (###, p 0.001) or ACEA (&&&, p 0.001) were determined by
a one-way ANOVA followed by post hoc Bonferroni’s tests.
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cross-talk in CB1-CB2 receptor heteromers, CB2 receptor,
mainly at the end of the light period, can negatively modulate
theCB1 receptor-mediated tetrahydrocannabinol effect on ary-
lalkylamine N-acetyltransferase activity and thus modulate
melatonin synthesis. Another brain region where the CB2
receptor expression was reported is the nucleus accumbens,
where CB2 receptor may be directly involved in many of the
neurochemical and motivational properties of cocaine that are
responsible for addiction (59). In fact, Xi et al. (59) found that
CB2 receptor agonists directly infused into the nucleus accum-
bens decreased the cocaine intake, CB2 receptors regulate the
psychomotor stimulant properties of cocaine, and CB2 recep-
tors are endogenously activated by endocannabinoids in
nucleus accumbens, where they control locomotor activity.
Because CB1 receptors are also expressed in the striatum (24,
28) and are reported to be involved in the locomotor activity
control (28), we determined the expression of CB1-CB2 recep-
tor heteromers in rat nucleus accumbens slices by PLA. We
found CB1-CB2 receptor heteromer expression in this brain
region. Although the CB2 receptor-mediated effects on loco-
motor activity are also seen in CB1/ mice (59), our results
provide a new perspective by which CB1 and CB2 receptors
might bemodulating each other to control locomotion through
CB1-CB2 receptor heteromers, using one partner as a “brake”
for the other partner’s actionwhen both are co-expressed in the
same neuron. CB1 receptors are extremely abundant, but CB2
receptors, at least in neurons, are thought to bemuch less abun-
dant. Altering the expression of CB2 receptors may provide a
possible level of regulation of CB1 receptor function by chang-
ing the amount of CB1-CB2 receptor heteromers. Further stud-
ies will have to be performed to investigate this possibility.
Finally, our data may provide explanations for several previ-
ously controversial points concerning CB1 and CB2 receptors.
A confounding problem with the cannabinoid receptors has
been the expression levels of the two receptors in the brain.
Specifically, there have been varying reports as to the amount of
CB2 receptor in the brain and whether those levels change in
pathological settings as well as speculation on the role of the
neuronal CB2 receptor (18, 31, 34, 35, 37, 38, 77–82). Our
results suggest that, even at low expression levels, CB2 recep-
tors could have a significant effect on signaling fromCB1 recep-
tor by reducing the cellular response through CB1 receptor.
This modulation could be up-regulated upon injury or disease,
supporting the thesis proposed recently byOnaivi (83) that CB1
and CB2 receptors can work independently and/or coopera-
tively in differing neuronal populations. This interdependence
in neurons expressing both receptors could be through hetero-
mers. At the ligand level, low and high levels of cannabinoid
receptor ligands have given different results (84, 85), which
were interpreted as affecting different populations of neurons,
or by the presence of another cannabinoid ligand-mediated
receptor, such as TRPV1 orGPR55, in the same neurons, but an
alternative explanation could also be the presence of receptor
heteromers. Conflicting results have also been observed on the
serotonin system at high and low doses of the nonspecific can-
nabinoid receptor agonistWIN55212,2. At lowdoses, therewas
an increase in neuronal excitation that decreased at higher con-
centrations. The authors argued these effects must be through
CB1 receptor because they could be blocked by the CB1 recep-
tor-specific antagonist, rimonabant. However, we show here
that a CB1 receptor antagonist could also block CB2 receptor-
mediated signaling via receptor heteromers. It would be inter-
esting to revisit these experiments using aCB2 receptor-specific
antagonist as well. Heteromers could also help explain seem-
ingly opposite effects seenwith the ligands 2-arachidonoylglyc-
erol and anandamide, which have been reported to have seem-
ingly opposite effects on striatal spiny neurons and sensory
neurons of the dorsal root ganglion (reviewed by diMarzo (86)).
Part of these effects could also be through differential signaling
via CB1-CB2 receptor heteromers. More studies will be
required to elucidate how these heteromers behave in different
tissues at different concentrations of these two endogenous
agonists. Another complication has been the discovery that
multiple isoforms of the CB2 receptors are expressed. Perhaps
the different isoforms of the CB2 receptor can differentially
modulate CB1 receptor and/or vice versa, depending on the
tissue environment. Further studies may provide a clue as to
how, at the mechanistic level, CB2 receptor is altering CB1
receptor signaling or vice versa and help clarify if any differ-
ences in isoforms exist. Finally, a third family of the cannabi-
noid receptors has recently been proposed, theGPR55 receptor
(87, 88), with which a functional interaction with CB2 receptor
has also been described (89, 90). It will be interesting to further
characterize its role, if any, in the brain and whether it too can
form heteromers with the other members of the family. In con-
clusion, we report the presence of CB1-CB2 receptor hetero-
mers in a variety of brain regions. These heteromersmay have a
profound impact on CNS function in a variety of neurological
and immunological systems, and our data suggest that these
heteromers must be taken into account when designing thera-
peutic approaches toward alterations involving the endocan-
nabinoid system.
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